Acceleron, Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at ASH
December 09, 2013 at 11:02 AM EST
Acceleron Pharma (NASDAQ: XLRN ) today announced that its collaboration partner Celgene (NASDAQ: CELG ) reported new interim data at the 55th American Society of Hematology (ASH) Annual Meeting of
